Cargando…
Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database
BACKGROUND: The effect of current therapies in improving the survival of lung cancer patients remains far from satisfactory. It is consequently desirable to find more appropriate therapeutic opportunities based on informed insights. A molecular pharmacological analysis was undertaken to design an im...
Autores principales: | Gemma, Akihiko, Li, Cai, Sugiyama, Yuka, Matsuda, Kuniko, Seike, Yoko, Kosaihira, Seiji, Minegishi, Yuji, Noro, Rintaro, Nara, Michiya, Seike, Masahiro, Yoshimura, Akinobu, Shionoya, Aki, Kawakami, Akiko, Ogawa, Naoki, Uesaka, Haruka, Kudoh, Shoji |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1533844/ https://www.ncbi.nlm.nih.gov/pubmed/16813650 http://dx.doi.org/10.1186/1471-2407-6-174 |
Ejemplares similares
-
Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation
por: Noro, Rintaro, et al.
Publicado: (2006) -
MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation
por: Noro, Rintaro, et al.
Publicado: (2015) -
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013) -
Exosome‐derived miR‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in EGFR mutant non‐small cell lung cancer cells
por: Hisakane, Kakeru, et al.
Publicado: (2021) -
MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells
por: CAO, MENGRU, et al.
Publicado: (2012)